ADMA vs. FDMT, AUTL, TARS, INBX, TWST, VIR, SRRK, NMRA, RXRX, and ADAP
Should you be buying ADMA Biologics stock or one of its competitors? The main competitors of ADMA Biologics include 4D Molecular Therapeutics (FDMT), Autolus Therapeutics (AUTL), Tarsus Pharmaceuticals (TARS), Inhibrx (INBX), Twist Bioscience (TWST), Vir Biotechnology (VIR), Scholar Rock (SRRK), Neumora Therapeutics (NMRA), Recursion Pharmaceuticals (RXRX), and Adaptimmune Therapeutics (ADAP). These companies are all part of the "biological products, except diagnostic" industry.
4D Molecular Therapeutics (NASDAQ:FDMT) and ADMA Biologics (NASDAQ:ADMA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, community ranking, media sentiment, analyst recommendations and institutional ownership.
4D Molecular Therapeutics presently has a consensus target price of $44.22, indicating a potential upside of 78.24%. ADMA Biologics has a consensus target price of $7.88, indicating a potential upside of 20.41%. Given ADMA Biologics' higher probable upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than ADMA Biologics.
In the previous week, 4D Molecular Therapeutics had 8 more articles in the media than ADMA Biologics. MarketBeat recorded 10 mentions for 4D Molecular Therapeutics and 2 mentions for ADMA Biologics. ADMA Biologics' average media sentiment score of 0.81 beat 4D Molecular Therapeutics' score of 0.56 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.
99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 10.7% of 4D Molecular Therapeutics shares are held by company insiders. Comparatively, 5.9% of ADMA Biologics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
ADMA Biologics received 368 more outperform votes than 4D Molecular Therapeutics when rated by MarketBeat users. Likewise, 71.48% of users gave ADMA Biologics an outperform vote while only 64.71% of users gave 4D Molecular Therapeutics an outperform vote.
ADMA Biologics has higher revenue and earnings than 4D Molecular Therapeutics. ADMA Biologics is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.
4D Molecular Therapeutics has a beta of 2.87, suggesting that its stock price is 187% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500.
ADMA Biologics has a net margin of -10.94% compared to ADMA Biologics' net margin of -436.30%. 4D Molecular Therapeutics' return on equity of 0.49% beat ADMA Biologics' return on equity.
Summary
ADMA Biologics beats 4D Molecular Therapeutics on 10 of the 19 factors compared between the two stocks.
Get ADMA Biologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADMA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ADMA Biologics Competitors List
Related Companies and Tools
